Article
Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.
Cell cycle (Georgetown, Tex.) - 1 Jan 2016
Lochhead Pamela A, Clark Jonathan, Wang Lan-Zhen, Gilmour Lesley, Squires Matthew, Gilley Rebecca, Foxton Caroline, Newell David R, Wedge Stephen R, Cook Simon J
Abstract excerpt
ERK5, encoded by MAPK7, has been proposed to play a role in cell proliferation, thus attracting interest as a cancer therapeutic target. While oncogenic RAS or BRAF cause sustained activation of the MEK1/2-ERK1/2 pathway, ERK5 is directly activated by MEK5. It has been proposed that RAS and RAF proteins can also promote ERK5 activation. Here we investigated the interplay between RAS-RAF-MEK-ERK and ERK5 signaling...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.